Form D · Other

Awakn Life Sciences Inc.

Toronto, A6 · CIK 0001869828

Offering snapshot reported Jun 29, 2021 · SEC filing

Reported sold
$1.64M
Offering amount: $1.64M
Investors reported
15
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 8, 2021
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 29, 2021Initial$1,639,346No comparison15SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired, Other
Exemptions
06b
Duration over one year
No
Business combination
Yes
Sales commissions
$61.7K
Finders' fees
$0
Form D file number
021-404488
U.S. dollare amounts are based on the Bank of Canada exchange rate 0.8267 reported on June 8, 2021.
Upon the satisfaction of the Release Conditions each Subscription Receipt will be automatically exchanged without additional consideration into 1 common share of the Issuer.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
CANACCORD GENUITY LLC1020

Source: Form D, filed Jun 29, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
James Collins Executive
Jonathan Held Director, Executive
Shaun Mc Nully Executive
George Scorsis Director
Benjamin Sessa Director, Executive
Anthony Tennyson Director, Executive

Issuer details

Industry: Other (See others in industry)

Address:
366 Bay Street, Suite 200
Toronto, A6, M5H 4B2